Skip to content
Open access

Crosstalk Between Donor T Cells and Recipient IL-33+ Target Tissue Stroma Controls Alloimmune Responses Causing Graft-versus-Host Disease 2260079

Jul 2026 · Journal of Immunology · Vol 215 · 0 citations

TL;DR

Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell transplantation (AlloHCT) and mechanisms releasing IL-33 from nuclear sequestration remain elusive, but free IL-33 directly activates donor CD4+ T cells to promote Th1 differentiation and expansion.

Abstract

Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell transplantation (AlloHCT). Conditioning with chemotherapy and radiation enables donor engraftment but causes tissue injury that upregulates the alarmin interleukin-33 (IL-33) in fibroblastic reticular cells (FRCs) in secondary lymphoid organs (SLO) and tissue stromal cells. While mechanisms releasing IL-33 from nuclear sequestration remain elusive, free IL-33 directly activates donor CD4+ T cells to promote Th1 differentiation and expansion. Early IL-33 blockade limits GVHD initiation, yet the role of local IL-33 in sustaining alloimmunity remains unclear. We used preclinical models to define how IL-33 signaling to donor T cells within SLO versus the gastrointestinal tract (GIT) stroma controls active GVHD and graft-versus-lymphoma (GVL) responses. BALB/c recipients received B6 T cell—depleted bone marrow, A20 lymphomas, and T cells from donors with inducible ST2 (IL-33R) deletion to control IL-33 signaling during GVHD and GVL. To identify stromal functions, B6 recipients lacking IL-33 in FRCs (CCL19-Cre×Il33fl/fl) or gut epithelium (Vil-Cre×Il33fl/fl) were transplanted with BALB/c T cells and bone marrow. T cell—dependent IL-33 release was tested using GzmB⁻/⁻, St2+/+, and St2⁻/⁻ T cells. Late ST2 deletion resolved GVHD without compromising GVL. IL-33 signaling increased Foxp3 levels and reduced T-bet expression in donor CD4+ T cells, while sustaining TCF-1. Unexpectedly, loss of FRC-derived IL-33 exacerbated GVHD, whereas gut epithelial IL-33 deletion was protective. IL-33 induced GzmB, and GzmB⁻/⁻ T cells displayed impaired activation and expansion. Early SLO-derived IL-33 establishes effector programming that influences later tissue responses. IL-33+ stroma—T-cell crosstalk programs donor CD4+ T-cell fate and shapes local alloimmunity during GVHD. IL-33—stroma feedback is a key signal to alloreactive T cells during GVHD. NIH/NIAID F30AI147437, NIH T32 CA082084, NIH/NHLBI R01HL122489, NIH/NIAID R21AI121981, NIH/NIAID R56AI13927 Transplantation Immunology (TRAN)

Read PDF

Similar papers

Review 2026

[Novel therapeutic strategies to separate GVHD from GVL based on GVHD pathophysiology and mechanisms of leukemia relapse].

Emerging strategies to ameliorate GVHD without attenuating GVL, including intensified local therapy, selective trafficking blockade, S1PR modulators that limit pathogenic T-cell migration, and tissue-protective agents that enhance epithelial regeneration and prevent the establishment of inflammatory memory are summariz...

Yumika Saito, D. Hashimoto · 0 citations
Open access Aug 2026

Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease - a First-in-Human Trial.

These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.

A. Tuettenberg, L. Ruhnke, J. Schlöder et al. · 0 citations
Open access Aug 2026

Recipient Endothelial IRF1 mediates IFNγ-driven tissue tolerance in mouse models of acute Graft-versus-Host Disease.

A role is identified for the lymphatic endothelial IFNγ-IRF1 axis in regulating early vascular remodeling, donor T cell mediated tolerance, underscoring a potential "goldilocks" level of pathway activation required to improve post-transplant outcomes.

Lotus Neidemire-Colley, Rathan Kumar, Elizabeth A. R. Garfinkle et al. · 0 citations
Aug 2026

CAR-T and GvHD: Have We Engineered GvHD Out of Allogeneic CAR‑T Therapy?

A focused Perspective asks whether GvHD directed engineering has made clinically significant product-associated GvHD rare and whether allogeneic CAR-T must reduce donor-to-host alloreactivity while managing the distinct host-versus-graft barrier.

Nabeel Ahmed, Jawaria Jabeen · 0 citations
Review Open access Sep 2026

Naive T cell-depleted hematopoietic stem cell transplantation to minimize immunosuppression after solid organ transplantation: case report

Two solid organ transplant recipients treated with non-myeloablative conditioning followed by naïve T-cell-depleted hematopoietic stem cell transplantation and donor memory T-cell infusions use mixed lymphocyte reactions with TCRβ sequencing to track donor-reactive T-cell clonotypes to support minimization of immunosup...

A. Pérez-Martínez, C. Aguirre-Portolés, C. Mestre-Durán et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.